Clinical Trial Update: Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis [Phase 1]

View source ↗

Summary

Phase 1 safety study of RTL1000 in individuals with multiple sclerosis is described, with the current trial status listed as unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• RTL1000 (recombinant T cell receptor ligand)

Snippet

Sponsor: Artielle ImmunoTherapeutics | Conditions: Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting | Phase 1 | Status: UNKNOWN